TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer.

Yardley, D. A.,Arrowsmith, E. R.,Daniel, B. R.,Eakle, J.,Brufsky, A.,Drosick, D. R.,Kudrik, F.,Bosserman, L. D.,Keaton, M. R.,Goble, S. A.,Bubis, J. A.,Priego, V. M.,P...; Breast Cancer Res. Treat.. 2017 May 17

Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial.

Yardley, D. A.,Dickson, N.,Drosick, D.,Earwood, C.,Inhorn, R.,Murphy, P.,Hainsworth, J. D.; Clin. Breast Cancer. 1900 Jan 01.

Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer.

Yardley, D. A.,Hart, L.,Waterhouse, D.,Whorf, R.,Drosick, D. R.,Murphy, P.,Badarinath, S.,Daniel, B. R.,Childs, B. H.,Burris, H.; Breast Cancer Res. Treat.. 2013 Nov 21